ES2103738T3 - Uso de acido eicosapentaenoico para el tratamiento de la caquexia. - Google Patents

Uso de acido eicosapentaenoico para el tratamiento de la caquexia.

Info

Publication number
ES2103738T3
ES2103738T3 ES90904918T ES90904918T ES2103738T3 ES 2103738 T3 ES2103738 T3 ES 2103738T3 ES 90904918 T ES90904918 T ES 90904918T ES 90904918 T ES90904918 T ES 90904918T ES 2103738 T3 ES2103738 T3 ES 2103738T3
Authority
ES
Spain
Prior art keywords
lipolytic
treatment
eicosapentaenoic acid
mammals
polyunsaturated fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90904918T
Other languages
English (en)
Inventor
Michael John Tisdale
Susan Anne Beck
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scotia Holdings PLC
Original Assignee
Scotia Holdings PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scotia Holdings PLC filed Critical Scotia Holdings PLC
Application granted granted Critical
Publication of ES2103738T3 publication Critical patent/ES2103738T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)

Abstract

SE EXPONE EL USO DEL ACIDO GRASO POLIINSATURADO OMEGA-3, ACIDO EICOSAPENTAEONICO, O EPA, PREFERIBLEMENTE LIBRE EN GRAN MEDIDA DE CUALQUIER OTRO ACIDO GRASO POLIINSATURADO, PARA FABRICACION DE PREPARADOS O COMPUESTOS MEDICINALES PARA EL TRATAMIENTO DE CACHEXIA Y/O TUMORES MALIGNOS EN MAMIFEROS Y PARA INHIBIR LA ACTIVIDAD LIPOLITICA DE AGENTES LIPOLITICOS BIOLOGICAMENTE ACTIVOS PRESENTES EN LOS FLUIDOS CORPORALES Y LA ACTIVIDAD DE LA ENZIMA GUANIDINOBENZOATASA, ASI COMO PARA REDUCIR NIVELES CAMP ANORMALES EN CELULAS O TEJIDOS ADIPOSOS EN MAMIFEROS, PRODUCIDOS POR SUSTANCIAS LIPOLITICAS O MOVILIZADORAS DE GRASA.
ES90904918T 1989-03-20 1990-03-20 Uso de acido eicosapentaenoico para el tratamiento de la caquexia. Expired - Lifetime ES2103738T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898906369A GB8906369D0 (en) 1989-03-20 1989-03-20 Eicosapentaenoic acid
SG137193A SG137193G (en) 1989-03-20 1993-12-21 Eicosapentaenoic acid

Publications (1)

Publication Number Publication Date
ES2103738T3 true ES2103738T3 (es) 1997-10-01

Family

ID=26295116

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90904918T Expired - Lifetime ES2103738T3 (es) 1989-03-20 1990-03-20 Uso de acido eicosapentaenoico para el tratamiento de la caquexia.

Country Status (11)

Country Link
EP (1) EP0464084B1 (es)
JP (1) JP3010310B2 (es)
AT (1) ATE155037T1 (es)
AU (1) AU643201B2 (es)
DE (1) DE69031033T2 (es)
DK (1) DK0464084T3 (es)
ES (1) ES2103738T3 (es)
GB (2) GB8906369D0 (es)
HK (1) HK2894A (es)
SG (1) SG137193G (es)
WO (1) WO1990011073A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000084A1 (en) * 1991-06-24 1993-01-07 Adelaide Children's Hospital Methods and compositions for treating malaria and other diseases
DE4304394A1 (en) * 1993-02-13 1993-09-02 Fresenius Ag Prepn. for nourishment of oncological patients - comprises fats formulation contg. oleic acid, alpha-linolenic acid, etc., and opt. carbohydrate and proteins
CA2119000A1 (en) * 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
NZ334852A (en) 1996-10-11 2001-05-25 Scotia Holdings Plc Use and preparation containing eicosapentaenoic acid (EPA; 20:5n-3) for treating schizophrenia
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
CN1268328C (zh) * 2001-05-30 2006-08-09 拉克斯戴尔有限公司 辅酶q与二十碳五烯酸(epa)
US20050215640A1 (en) * 2004-03-26 2005-09-29 Baxter Jeffrey H HMB compositions and uses thereof
EP2025248A1 (en) * 2007-07-31 2009-02-18 Fresenius Kabi Deutschland GmbH Cachexia prevention supplement
WO2009149496A1 (en) * 2008-06-10 2009-12-17 Central Northern Adelaide Health Service Treatment of diabetes and complications thereof and related disorders
PL2334295T3 (pl) 2008-09-02 2017-12-29 Amarin Pharmaceuticals Ltd Kompozycja farmaceutyczna zawierająca kwas eikozapentaenowy i kwas nikotynowy oraz sposoby jej zastosowania
MX2011008448A (es) 2009-02-10 2012-02-28 Amarin Pharma Inc Uso de ester etilico del acido eisosapentaenoico para tratar hipertrigliceridemia.
CN102458109B (zh) 2009-04-29 2015-02-11 阿马里纳制药公司 稳定的药物组合物和使用其的方法
EP2424521A4 (en) 2009-04-29 2015-03-04 Amarin Pharmaceuticals Ie Ltd PHARMACEUTICAL COMPOSITIONS COMPRISING EPA AND CARDIOVASCULAR AGENT AND METHODS OF USE
KR102012111B1 (ko) 2009-06-15 2019-08-19 아마린 파마, 인크. 병용 스타틴 요법을 받는 대상체에서 ｌｄｌ－ｃ 수준을 상승시키지 않으면서 트리글리세리드를 저하시키기 위한 조성물 및 방법
SG10201405994UA (en) 2009-09-23 2014-10-30 Amarin Pharmaceuticals Ie Ltd Pharmaceutical Composition Comprising Omega-3 Fatty Acid And Hydroxy-derivative Of A Statin And Methods Of Using Same
NZ712068A (en) 2010-11-29 2017-03-31 Amarin Pharmaceuticals Ie Ltd Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11712429B2 (en) 2010-11-29 2023-08-01 Amarin Pharmaceuticals Ireland Limited Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
US11291643B2 (en) 2011-11-07 2022-04-05 Amarin Pharmaceuticals Ireland Limited Methods of treating hypertriglyceridemia
EP2775837A4 (en) 2011-11-07 2015-10-28 Amarin Pharmaceuticals Ie Ltd METHODS OF TREATING HYPERTRIGLYCERIDEMIA
WO2013103958A1 (en) 2012-01-06 2013-07-11 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
SG11201408769QA (en) 2012-06-29 2015-01-29 Amarin Pharmaceuticals Ie Ltd Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
US20150265566A1 (en) 2012-11-06 2015-09-24 Amarin Pharmaceuticals Ireland Limited Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy
US9814733B2 (en) 2012-12-31 2017-11-14 A,arin Pharmaceuticals Ireland Limited Compositions comprising EPA and obeticholic acid and methods of use thereof
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
US9452151B2 (en) 2013-02-06 2016-09-27 Amarin Pharmaceuticals Ireland Limited Methods of reducing apolipoprotein C-III
US9624492B2 (en) 2013-02-13 2017-04-18 Amarin Pharmaceuticals Ireland Limited Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
US9662307B2 (en) 2013-02-19 2017-05-30 The Regents Of The University Of Colorado Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
US9283201B2 (en) 2013-03-14 2016-03-15 Amarin Pharmaceuticals Ireland Limited Compositions and methods for treating or preventing obesity in a subject in need thereof
US20140271841A1 (en) 2013-03-15 2014-09-18 Amarin Pharmaceuticals Ireland Limited Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
US10966968B2 (en) 2013-06-06 2021-04-06 Amarin Pharmaceuticals Ireland Limited Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
US20150065572A1 (en) 2013-09-04 2015-03-05 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing prostate cancer
US9585859B2 (en) 2013-10-10 2017-03-07 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
US10561631B2 (en) 2014-06-11 2020-02-18 Amarin Pharmaceuticals Ireland Limited Methods of reducing RLP-C
US10172818B2 (en) 2014-06-16 2019-01-08 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
US10406130B2 (en) 2016-03-15 2019-09-10 Amarin Pharmaceuticals Ireland Limited Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
KR20190118556A (ko) 2016-12-23 2019-10-18 바스프 에이에스 악액질의 예방 및/또는 치료용 오메가-3 지방산 조성물
TW201900160A (zh) 2017-05-19 2019-01-01 愛爾蘭商艾瑪琳製藥愛爾蘭有限公司 用於降低腎功能下降之個體中的三酸甘油酯之組合物及方法
US11058661B2 (en) 2018-03-02 2021-07-13 Amarin Pharmaceuticals Ireland Limited Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
KR102296068B1 (ko) 2018-09-24 2021-09-02 애머린 파마슈티칼스 아일랜드 리미티드 대상체에서 심혈관 사건의 위험도를 감소시키는 방법
KR20240012390A (ko) 2021-04-21 2024-01-29 애머린 파마슈티칼스 아일랜드 리미티드 심부전의 위험을 감소시키는 방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1225597A (en) * 1982-09-22 1987-08-18 Jakobus Booyens Prophylactic substance or composition
EP0175468A3 (en) * 1984-08-10 1987-07-22 Sentrachem Limited Eicosanoids for use in cancer therapy
JPS63303925A (ja) * 1987-06-05 1988-12-12 Nippon Oil & Fats Co Ltd 制癌剤組成物
GB8806471D0 (en) * 1988-03-18 1988-04-20 Tisdale M J Biologically active material characterised by catabolic activity generally associated with cachexia inducing tumours
GB2223943A (en) * 1988-10-21 1990-04-25 Tillotts Pharma Ag Oral disage forms of omega-3 polyunsaturated acids
DE3901048A1 (de) * 1989-01-14 1990-07-19 Chimicasa Gmbh Antikachectikum
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids

Also Published As

Publication number Publication date
GB2229363A (en) 1990-09-26
GB2229363B (en) 1993-06-02
GB8906369D0 (en) 1989-05-04
AU5331090A (en) 1990-10-22
GB9006256D0 (en) 1990-05-16
ATE155037T1 (de) 1997-07-15
WO1990011073A1 (en) 1990-10-04
DE69031033T2 (de) 1997-11-20
JP3010310B2 (ja) 2000-02-21
SG137193G (en) 1994-03-31
JPH05504936A (ja) 1993-07-29
HK2894A (en) 1994-01-21
EP0464084B1 (en) 1997-07-09
EP0464084A1 (en) 1992-01-08
DK0464084T3 (da) 1997-08-11
AU643201B2 (en) 1993-11-11
DE69031033D1 (de) 1997-08-14

Similar Documents

Publication Publication Date Title
ES2103738T3 (es) Uso de acido eicosapentaenoico para el tratamiento de la caquexia.
IL137848A0 (en) Indole-3-propionic acids, salts and esters thereof used as medicaments
TR200000178T2 (tr) Asal yağlı asitleri ve biyoaktif disülfitleri içeren terapötik ve diyetsel bileşimler.
IT1176916B (it) Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
DK0764405T3 (da) Ernæringspræparat
BR0112073A (pt) Combinações terapêuticas de ácidos graxos
BR0208984A (pt) ácidos graxos, glicerìdeos e análogos de comprimento de cadeia médio como fatores de sobrevivência e ativação de neutrófilos
FI853431L (fi) Hjaelpaemne foer utbredning av ett farmaceutiskt verkande aemne pao huden.
DE3379568D1 (en) Surfactant treatment of implantable biological tissue to inhibit calcification
BR0307041A (pt) Corpos de fosfolipìdio e uso dos mesmos no tratamento de doenças inflamatórias e autoimunes
IS2257B (is) Samsetning með aselínsýru
FI850354L (fi) Kompositioner foer anvaendning vid kosmetisk, haelso- och kroppsvaord.
US5891083A (en) Suction lipolysis
DE3878812D1 (de) Omega-3-fettsaeuren zur behandlung von traumatischen verwundungen.
CA2052577A1 (en) Therapeutic uses of eicosapentaenoic acid
SE8102161L (sv) "3,7,11,15-tetrametyl-2,4,6,10,14-hexadekapentaensyra
SE8800990L (sv) Hudregenererande kosmetisk komposition samt foerfarande foer framstaellning av densamma
ATE128964T1 (de) Anwendung von beta-alethin in zellkultur und therapie.
Murrell II. Scientific comment basic science of Dupuytren's disease
KR20220016318A (ko) 관절 염증 개선 및 연골 보호를 위한 홍합 추출유 복합물 및 크릴 추출유를 포함하는 조성물
ES2031462T3 (es) Procedimiento para producir 1-b-d-arabinofuranosilcitosina-5'-estearilfosfato monosodico y monohidrato de la misma, y compuesto farmaceutico que contiene esta ultima.
SU577051A1 (ru) Способ обработки хирургических материалов и изделий
KR950005917B1 (ko) 솔잎 추출물〈pine essential oil, pine absolute 및 pine concrete〉을 첨가한 미용 비누
AU3054100A (en) Novel use of phospholipids of vegetable and animal origin in nutritional therapy
TH6683A (th) องค์ประกอบของการรักษาผิวหนัง

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 464084

Country of ref document: ES